The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from Business Wire

Teva Files 2012 Annual Report on Form 20-F

Friday, March 08, 2013

Teva Files 2012 Annual Report on Form 20-F16:01 EST Friday, March 08, 2013 JERUSALEM (Business Wire) -- In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it has filed its 2012 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The Annual Report can be found on the company's website at www.tevapharm.com as well as on the SEC website at www.sec.gov. In addition, security holders may request a hard copy of the Annual Report, which includes the company's complete audited financial statements, free of charge. Requests can be made by contacting Teva Investor Relations at 1090 Horsham Road, North Wales PA, 19454 or by phone at (215) 591-8912 or 011-972-3-926-7656. About Teva Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $20.3 billion in net revenues in 2012. Teva Pharmaceutical Industries Ltd.IR:United StatesKevin C. Mannix, 215-591-8912Kristen Frank, 215-591-8908orIsraelTomer Amitai, 972 (3) 926-7656orPR:IsraelHadar Vismunski-Weinberg, 972 (3) 926-7687orUnited StatesDenise Bradley, 215-591-8974